Data from an ongoing phase I trial turned up even better than many expected with ALN-PCS, the subcutaneously given RNAi proprotein convertase subtilisin/kexin type 9 (PCSK9) blocker in the works by Alnylam Pharmaceuticals Inc. and The Medicines Co. for lowering LDL-C.